Nucleolar protein TAAP1/ C22orf46 confers pro-survival signaling in non-small cell lung cancer

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung



Tumor cells subvert immune surveillance or lytic stress by harnessing inhibitory signals. Hence, bispecific antibodies have been developed to direct CTLs to the tumor site and foster immune-dependent cytotoxicity. Although applied with success, T cell-based immunotherapies are not universally effective partially because of the expression of pro-survival factors by tumor cells protecting them from apoptosis. Here, we report a CRISPR/Cas9 screen in human non-small cell lung cancer cells designed to identify genes that confer tumors with the ability to evade the cytotoxic effects of CD8 + T lymphocytes engaged by bispecific antibodies. We show that the gene C22orf46 facilitates pro-survival signals and that tumor cells devoid of C22orf46 expression exhibit increased susceptibility to T cell-induced apoptosis and stress by genotoxic agents. Although annotated as a non-coding gene, we demonstrate that C22orf46 encodes a nucleolar protein, hereafter referred to as "Tumor Apoptosis Associated Protein 1," up-regulated in lung cancer, which displays remote homologies to the BH domain containing Bcl-2 family of apoptosis regulators. Collectively, the findings establish TAAP1/ C22orf46 as a pro-survival oncogene with implications to therapy.


FachzeitschriftLife science alliance
PublikationsstatusVeröffentlicht - Apr. 2024

Externe IDs

PubMedCentral PMC10791977
Scopus 85182613998


Ziele für nachhaltige Entwicklung


  • Humans, Carcinoma, Non-Small-Cell Lung/metabolism, Lung Neoplasms/metabolism, Nuclear Proteins, Antibodies, Bispecific/therapeutic use, Antineoplastic Agents/pharmacology